The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery

J Cardiothorac Vasc Anesth. 2004 Feb;18(1):53-8. doi: 10.1053/j.jvca.2003.10.011.

Abstract

Objectives: Perioperative treatment with angiotensin-converting enzyme (ACE) inhibitors in cardiac surgery with cardiopulmonary bypass is still controversial. Using ACE inhibitors during cardiac surgery might be associated with an increased risk of critical hypotensive episodes. On the other hand, ACE inhibitors could have beneficial effects with respect to the development of the systemic inflammatory response syndrome.

Design: The effect of acute administration of quinaprilat on hemodynamic variables and plasma cytokines was assessed under double-blind, randomized, and placebo-controlled conditions.

Setting: Department of anesthesiology and cardiovascular surgery clinic in a university hospital.

Participants: Forty patients without preexisting cardiac failure, undergoing coronary artery bypass grafting.

Interventions: Patients received 0.08 mg/kg of intravenous quinaprilat or intravenous isotonic saline solution after induction of anesthesia.

Measurements and results: Blood samples were taken after induction of anesthesia (T0), before cardiopulmonary bypass (T1), at the end of surgery (T2), and 4 hours after the end of surgery (T3). There was no difference between the 2 groups regarding mean arterial pressure and inotropic or vasopressor support. Systemic vascular resistance index was significantly lower in the quinaprilat group at T2 (p = 0.016) and T3 (p = 0.017). No difference in proinflammatory cytokine levels was observed between the 2 groups.

Conclusions: The present investigation shows that acute administration of an intravenous ACE inhibitor, quinaprilat, has no influence on proinflammatory cytokines during cardiac surgery with cardiopulmonary bypass. The patients treated with quinaprilat showed an improved systemic vascular resistance index with no increased risk of deleterious hemodynamic episodes.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / blood
  • Angiotensin II / drug effects
  • Angiotensin-Converting Enzyme Inhibitors / blood
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Cardiac Output / drug effects
  • Coronary Artery Bypass*
  • Cytokines / blood*
  • Double-Blind Method
  • Female
  • Hemodynamics / drug effects*
  • Humans
  • Injections, Intravenous
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-10 / blood
  • Isotonic Solutions / administration & dosage
  • Male
  • Middle Aged
  • Prospective Studies
  • Sialoglycoproteins / blood
  • Sialoglycoproteins / drug effects
  • Sodium Chloride / administration & dosage
  • Tetrahydroisoquinolines / blood
  • Tetrahydroisoquinolines / pharmacology*
  • Time Factors
  • Tumor Necrosis Factor-alpha / drug effects

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Cytokines
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Isotonic Solutions
  • Sialoglycoproteins
  • Tetrahydroisoquinolines
  • Tumor Necrosis Factor-alpha
  • Angiotensin II
  • Interleukin-10
  • quinaprilat
  • Sodium Chloride